February 21, 2023 02:53 PM ESTUpdated 03:04 PM
Pharma

Big Phar­ma has harsh words for UK's bal­loon­ing vol­un­tary re­im­burse­ment agree­ment

Paul Schloesser

Associate Editor

In the af­ter­math of Ab­b­Vie and Eli Lil­ly leav­ing the UK’s vol­un­tary drug pric­ing agree­ment in Jan­u­ary, some Big Phar­ma ex­ecs are still rais­ing ques­tions …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times